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As cancer stem cells (SCs) drive tumor growth, it is only
through the elimination of those cancer SCs that a
pharmacologic cure can be attained. To study ways to
develop drugs that target cancer SC, we investigated changes
in cellular mechanisms and kinetics that occur in SC
populations during colorectal cancer (CRC) development.
We used computer modeling to determine which changes
could give rise to exponential increases in both SC and non-
SC populations in CRC. Our results show that the only
mechanism that can explain how these subpopulations
increase exponentially in CRC development involves an
increase in symmetric SC cell division. This finding suggests
that any systemic therapies designed to effectively treat CRC
and other cancers must act to control or eliminate
symmetrical cancer SC division in tumors, while minimally
affecting normal SC division in non-tumor tissues.
Curing cancer in its advanced stages is difficult. This may be
due to the current systemic treatment approach in which
chemotherapeutic agents are designed to kill rapidly
proliferating cells, which make up the bulk of tumors.
Among the many reasons why chemotherapy does not kill all
malignant cells in a cancer, three seem particularly salient: (1)
some cells in tumors are insensitive to chemotherapy through
mechanisms such as multidrug resistance; (2) Chemother-
apeutic agents are not specific enough and kill normal cells as
well, and this toxicity limits the maximal tolerable dose; (3)
some proliferative cells in tumors are not proliferating.
However, new insights towards more effective treatment
approaches are emerging from a new tenet in oncology – that
cancers arise from adult stem cells (SCs) and that cancer SCs
drive tumor growth.1–3 Indeed, SCs are known to be
quiescent or only slowly proliferating and inherently possess
mechanisms for drug resistance such as multidrug resistance.
As a result, cancer SCs are becoming recognized as a
necessary target for effective anticancer therapy.1,4
In this view, the task now is to control or eliminate cancer
SC populations. To this end, we will need to identify
mechanisms by which cancer SC drive tumor growth and to
target those mechanisms. Identifying such mechanisms will,
necessarily, require an understanding of mechanisms that give
rise to the unique properties of SC in normal tissues (Table 1)
and how these mechanisms become altered when a normal SC
becomes a cancer SC. Accordingly, we focused on tumor
growth in colonic tissue and developed a mathematical model
to explore likely cellular mechanisms of that tumor growth.
An approach that we thought was both novel and key was
to study the changes in cell populations in tissues that are
characteristic of cancer development. We thus designed a
mathematical model to study the dynamics of cell popula-
tions (rather than what happens to individual cells) and how
changes in these dynamics might affect the various cell
populations in colonic tissues during colorectal cancer (CRC)
development. As part of our modeling, we used information
from recent studies regarding cell populations in colonic
tumors, studies that show that within each CRC a small but
significant proportion (0.25–2.5%) of tumor cells are cancer
SCs.5,6 As CRCs contain an exponentially increased number
of neoplastic cells (108–1013), the size of the SC population
must also have increased exponentially. If SCs in tumors
continue to be B1% of the total cell population of the
tumor, then the increase must have been from about 20 SCs
in the normal crypt to 106–1011 cancer SCs in a colon cancer.
The purpose of our modeling study was to determine what
changes could give rise to such exponential increases in SC
and non-SC populations. We approached this with the
objective of identifying key mechanisms in tumor growth
that represent targets for new, potentially curative pharma-
cological approaches to cancer treatment.
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RESULTS
We structured a biologically relevant model based on
biological evidence. There are four types of cell populations
in our model: SC, IC, NC, and eradicated cell. Dynamics of
these four types of cell populations are described by
mechanisms and rate reactions shown in Figures 1 and 2
and their properties are given in Table 1. SC and IC represent
proliferative cells. As shown in Figure 2a, SC divide either
symmetrically to form two SC (Rxn 1), two IC (Rxn 3), or
asymmetrically to form an SC and an IC (Rxn 2). SC can also
become NC (Rxn 4). The SC population is self-renewing
through symmetric (Rxn 1) and asymmetric (Rxn 2) SC
division. IC divides symmetrically to form two IC (Rxn 5) or
become NC (Rxn 6). The IC population is normally not self-
renewing and maintenance of the IC population requires
production of new IC through SC division (Rxns 2 and 3).
NCs are produced from SC (Rxn 4) and IC (Rxn 6), and
production of NC is not a product of cell division. NCs
do not divide, but can be lost from the system through
the process of eradication, i.e., eradicated cell production
(Rxn 7).
Computer modeling of normal colonic crypt populations
(Figure 3a) generated output showing a constant number of
SC, intermediate cell (IC), and non-proliferative cell (NC)
with time, which is consistent with a steady-state condition.
Increasing (20 ) the rate of asymmetric SC division (Rxn 2)
produced an increase in IC and NC, but not in SC (Figure
3b). In this case, the number of IC and NC asymptotically
approached a maximum in the range of 10,000–40,000 cells at
4 years (B35,000 h). In contrast, increasing the rate of
symmetric IC division (Rxn 5) and of symmetric SC division
(Rxn 1) produced an exponential increase in total cell
number over time (Figure 3c and d). Figure 3c shows that
increasing symmetric IC division (by as little as 1.2 )
produces a rapid exponential increase in IC and NC number
(4109 cells byB0.25 year orB2,000 h), but did not increase
SC number. In contrast, Figure 3d shows that increasing
symmetric SC division (20 ) produces a slow exponential
increase (total cells 4109) over 4 years (B35,000 h) in IC,
NC, and SC. In this case, SC (B108) represents a small
subpopulation (B3%) of the total cell population. Decreas-
ing the type of symmetric SC division that produces two ICs
(Rxn 3) had minimal effect on SC or IC number, probably
because the slight increase in SC number due to decreased SC
loss is offset by a decrease in IC production (data not shown).
Decreasing the rate of production of NCs from SC (Rxn 4)
Table 1 Properties of SC, IC, and NC populations
Population property SC population IC population NC population
Self-renewal SC population is able to independently
maintain itself
Maintenance of the IC population
depends on the SC population
Maintenance of the NC population
depends on the SC and IC populations
Capacity for multi-
lineage differentiation
SCs are undifferentiated cells with the
capacity for producing a variety of
differentiated cell types
ICs are committed to produce specific
differentiated cell types
NCs are terminally differentiated,
apoptotic or terminally injured by
cytotoxic agents (radiation,
chemotherapeutics, etc)
Proliferative capacity Proliferative cells having the capacity for
cell division over the lifetime of the host
organism
Proliferative cells having the capacity for
cell division over the short-term
Non-proliferative cells having zero
capacity for cell division
Fraction of overall cell
population
Small (B1%) Large Large
Proliferation status SCs are quiescent or slowly proliferating ICs are rapidly proliferating NCs are nonproliferating
Capacity for tissue
renewal
SCs have the capacity for ongoing tissue
renewal and tissue generation during
development and regeneration after
injury
ICs have lost the capacity for ongoing
tissue renewal and tissue generation
during development and regeneration
after injury
NCs have zero capacity for ongoing
tissue renewal and tissue generation
during development and regeneration
after injury
IC, intermediate cell; NC, nonproliferative cell; SC, stem cell.
Stem cell population 
(including progenitor 
cell population)
Intermediate cells 
(non-stem 
proliferative cell 
population)
Non-proliferative cell 
population
Eradicated cell
population
SC IC NC EC
Figure 1 Model for the proliferative kinetics of normal and malignant tissues. There are four types of cell populations in our model: SC, IC, NC, and
eradicated cell. SC and IC represent proliferative cells. Although the SC population is self-renewing, the IC population is normally not self-renewing and
maintenance of the IC population requires production of new IC through SC division. NCs are produced from SCs and ICs and production of NCs is not a
product of cell division. NCs do not divide, but can be lost from the system through the process of eradication, i.e., eradicated cell production.
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had only a modest effect on increasing SC and IC number (an
increase of less than 3,000 cells over 30,000 h – data not shown).
DISCUSSION
Results from our modeling not only provide insight into cell
kinetic mechanisms that drive tumor growth, but also have
implications for developing new approaches toward cancer
treatment. Our previous studies7–9 provided evidence sug-
gesting that SCs are overproduced in the initiation and
progression steps of human colon tumorigenesis. Two more
recent studies5,6 provided important information that cancer
SCs are contained in human CRCs and that they represent
about 1% of the total number of cells within the tumor.
These results are consistent with studies showing that various
cancer types, including malignancies of the breast,10 pan-
creas,11 head and neck,12 neurologic,13–15 and hematologic
system,16–21 also contain a small fraction (B1%) of cancer
SCs. As cancers, including CRC, at the time of diagnosis
contain an exponentially increased number of tumor cells
(108–1013) relative to normal tissues, the cancer SC popula-
tion within tumors must also have increased exponentially
(106–1011 cells).
As cancer SCs drive tumor growth, it is only through the
elimination of those cancer SCs that a cancer cure can be
attained. It follows, then, that the most productive research
approach to develop effective anticancer therapies is to focus
on changes in cellular mechanisms and kinetics that occur in
SC populations during cancer development.
The specific question we asked was – which reaction in cell
population dynamics, when changed, can account for the
biologic characteristics of CRC development? This was done
by seeing if model output fit with three of these character-
istics: (i) CRC development leads to an exponential increase
in both SC and non-SC, (ii) CRC development involves
maintenance of a small but relatively constant ratio of SC/
non-SC number, and (iii) CRC development takes a
considerably long time (2–10 years). In considering the seven
reactions shown in Figures 1 and 2, changes in only one of
them, reaction 1, explained the above biological character-
istics of CRC development. The output of our model for that
perturbation showed (1) an exponential increase (4108 cells)
in both SC and non-SC populations (IC and NC), (2) a
relatively constant SC/total cell population ratio (B3%), and
(3) a relatively long time period (B4 years) before the
exponential increase in cell number was reached. Model
output from perturbations of any of the other six rate
constants shown in Figure 2 was unable to account for these
three biological characteristics. In this view, when the rate of
symmetrical SC division increases, then SC population size
increases which, in turn, increases IC population size through
SC asymmetric cell division. Both increased SC and IC
population sizes will lead to an increase in NC population
size. Consequently, increased symmetric SC cell division
would result in exponential growth of all three populations,
SC, IC, and NC.
So what are the clinical implications of our results that
indicate increased SC division is the driving force for cancer
growth? For one, there needs to be an effort to develop drugs
that specifically target symmetric SC division of cancer SCs.
This is a challenging task because it will be necessary to
distinguish cell pathways involved in regulating the two
different processes involved in SC self-renewal – symmetric
versus asymmetric SC division. This task will have to address
the fact that any potential drug that has a major inhibitory
effect on asymmetric SC division will only inhibit production
of IC, not reduce cancer SC numbers. Nonspecifically
inhibiting asymmetric SC division (a mechanism sometimes
misconstrued to be the only process involved in SC self-
renewal) would carry potential toxicity to normal tissue
because our modeling indicates that this type of SC division
is a main mechanism that maintains the IC population,
which biologically corresponds to normal tissue renewal.
Drugs that non-selectively inhibit symmetric IC division
would theoretically be similar to our present day pharma-
ceutical platform of chemotherapy agents, namely, they are
designed to generically kill proliferating cells and carry
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Figure 2 Kinetic relationships of cell populations. The mechanisms and
equations in this Figure describe the kinetics for populations of (a) SCs, (b)
ICs, (c) and NCs. The columns list reactions that lead to gain, no change, or
decrease in cell numbers within the given population. The equation that
describes the changes in SC, IC, or NC number with respect to time is given
at the bottom of each figure.
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significant toxicity due to adverse effects on proliferating
populations in normal tissues.
Another implication is that it will be necessary to identify
which pathways that normally regulate symmetric SC
division are altered in cancer SCs compared to normal cells.
This is because any potential drug that does not selectively
inhibit symmetric SC division in cancer tissues will have
negative effects on symmetric SC division in normal tissues.
Indiscriminately inhibiting symmetric SC division would also
carry significant potential toxicity to normal tissues because
our modeling indicates that this type of SC division is
maintaining the SC population by counterbalancing SC loss.
This could have adverse consequences due to toxicity from
inhibiting normal tissue replacement (e.g., via crypt fission)
and repair of injured tissue.
Thus, the promise and challenge of the future for new and
potentially curative cancer therapies lies in research on
normal and cancer SCs. Currently, although the field is
making advances at a relatively fast pace, it is still in its early
stages of discovery. For instance, current studies on cancer
SCs are mainly investigating the same pathways (e.g., wnt,
hedgehog, notch, PTEN, etc) to identify their roles in the
different tumor types.22,23 Given that the SCs in each tissue
carry the genetic and cellular program that is responsible for
the distinct organization and function of each tissue, it will be
necessary to eventually determine which pathways are
different in SCs in different tissues. Another challenge in
developing drugs that selectively target symmetric SC
division is that we will need specific SC markers to identify
and isolate SCs, ways to measure the effect of agents on
symmetric SC division, and methods to measure response of
potential drugs on SCs in vitro and in vivo. This latter point
will be challenging because cancer SCs are few in number and
they are slowly proliferating so tumor responses may be slow
and current methods of measuring antitumor responses will
probably not apply to assessing the effect from an anti-SC
drug. Nonetheless, although there is much work to be done
in this field, cancer research appears to now have finally taken
the first step in the right direction toward developing new
anticancer therapies that have the potential to cure cancer
patients.
METHODS
Kinetic relationships of cell populations. The kinetic relation-
ships of cell populations in our model were based on biological
evidence.22,23 SC population: Reactions shown in Figure 2a indicate
that the number of SC will increase by symmetric SC division, SC-
2 SCs (Rxn 1). The number of SC will decrease by processes
described by SC-2 ICs (Rxn 3) and SC-NC (Rxn 4). In
asymmetric SC division, SC-SCþ IC (Rxn 2), the number of SCs
does not change. Based on this logic, the change in SC number with
time is described by Eq. 1, which accounts for both SC production
and SC loss.
IC population: Overall, the number of ICs (Figure 2b) is
increased by another type of symmetric SC division, SC-2 ICs
(Rxn 3), asymmetric SC division, SC-SCþ IC (Rxn 2), and by
symmetric IC division, IC-2 ICs (Rxn 5). The number of ICs will
be decreased by IC growth termination IC-NC (Rxn 6). The
change in IC number with time is described by Eq. 2, which
accounts for both IC production and IC loss. As, by definition, the
IC population is normally not self-renewing, k64k5 in Eq. 2.
NC population: Overall, the number of NC (Figure 2c) will be
increased by termination of SC growth, SC-NC (Rxn 4) and
termination of IC growth, IC-NC (Rxn 6). The number of NC will
be decreased by eradication of NC from the system, NC-eradicated
cell (Rxn 7). The change in NC number with time is described by
Eq. 3, which accounts for both NC production and NC loss.
Kinetic relationships of cell populations in tissues. Normal tissues:
In healthy normal tissues, cell populations are in steady state, i.e., the
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Figure 3 Model simulations. (a) Model output for normal colonic crypt populations showing a constant number of SC, IC, and NC with time, which is
consistent with a steady-state condition in the colon crypt. (b) Output from increasing (20 ) asymmetric SC division showing that the number of IC and NC
asymptotically approaches a maximum, but SC does not increase. (c) Output from increasing (by as little as 1.2 ) symmetric IC division and showing a rapid
exponential increase in IC and NC, but not SC number. (d) Output from increasing (20 ) symmetric SC division, showing a slow exponential increase in IC,
NC, and SC. In this case, SCs represent a small subpopulation (B3%) of the total cell population. Note each relative time unit of computer output is equal to
B1 h (X axis) and thus 8,760 time units¼B1 year.
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number of cells produced is balanced by the number lost. Thus,
change in the number of cells in proliferative (SC and IC), NC and
total cell populations will be 0. The steady-state conditions
expressed in equation form are:
For the SC population : k1 ¼ k3 þ k4 ðEq: 4Þ
For the IC population : ðk2 þ 2k3Þ½SC ¼ ðk6  k5Þ½IC ðEq: 5Þ
For the NC population : k4½SC þ k6½IC ¼ ðk7Þ½NC ðEq: 6Þ
Each equation above accounts for the balance, at steady state,
between cell production (left side of equation), and loss (right side
of equation).
Malignant tissues: In cancers, cell populations are not in steady
state, cell production is greater than cell loss, and SC, IC, and NC
increase with time. Thus, for the malignant tissue case, the left side
(expression for cell production) of each equation (Equations 4–6) is
greater than the right side (cell loss).
Characteristics of colon cell populations. Like the cell population of
the normal human colonic crypt, the normal cell population in our
model containsB3,000 cells. Of these, 1,000 are ICs, 2,000 are NCs,
and 20 (B1%) are SCs. The model crypt renews every 5 days and
the average cell cycle time is 30 h. In the model, colon cancer arises
from changes in the normal cell population. Simulated cancers, like
biologic CRCs, typically contain 108–1013 cells. In the model, tumors
contain SC, IC, and NC. The simulated cancer has an SC:total cell
ratio (i.e., SC/(SCþ ICþNC)) that is approximately equal to the
same ratio in the normal model cell (20:3,020).
Rate constant values. Symmetric IC division: The rate constant
value for symmetric division of IC was estimated from the biologic
cell cycle time of human colonocytes (average of 30 h).24 Using this
average cell cycle time and according to standard rate equation
calculations,25 the rate constant k5 for symmetric IC division is
estimated to be 0.023/h.
Asymmetric SC division: The rate constant value for asymmetric
division of SC was estimated from the cell cycle time (100 h) of SCs
at the bottom of the normal crypt (Bach et al.,26 BMB, and OAR
unpublished data). Using this SC cycle time and standard rate
equations, the rate constant k2 for SC asymmetric IV division is
estimated to be 0.00693/h.
Symmetric SC division: The rate constant value for symmetric
division of SC was estimated from biologic information indicating
that only one out of every 300 crypts undergoes crypt fission at any
given time and that crypt fission is a process that results from
symmetric SC division.27–30 Thus, in the model, symmetric SC
division is 300 times slower than asymmetric SC division and k1 is
estimated to be 0.000023. In contrast to the normal biological colon,
in neoplastic colonic epithelium of familial adenomatous polyposis
patients, one in 15 crypts undergoes crypt fission at any given
time.29 Thus, in modeling cancer we assumed that k1 for
symmetrical SC division is 0.0046/h. Values for other rate constants
were set based on the expressions in Eq. 4–6 and that the IC
population is by definition not self renewing under normal
conditions (i.e., k64k5).
Computer modeling. Rate equations were written and then solved
using Mathematica equation-solving software (version 5.2, Wolfram
Research, Champaign, IL). The estimated rate constant values were
used for modeling steady state conditions in normal colonic crypts
(Methods) and then the rate constants were individually increased
or decreased to study effects of perturbations on different cell
populations. Model output was graphically displayed as number of
SC, IC, and NC cells (Y axis) versus time (X axis). As rate constant
values are expressed per hour, each relative time unit of computer
output is equal to B1 h and 8,760 output units¼ 1 year.
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